ClinicalTrials.gg
Not yet recruitingNCT06270524C5-MAG4Updated Jun 26, 2024

Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target

An interventional study of Blood sampling in Immunoglobulin G4-Related Disease, sponsored by Assistance Publique Hopitaux De Marseille. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups: healthy subjects without MAG4 and patients with MAG4 in remission.

Read the detailed description

IgG4-associated disease is a rare fibrosing and inflammatory disorder whose pathophysiology remains poorly understood. Activation of certain monocyte/macrophage populations (in particular M2-type macrophages) has been shown to be involved during the course of the disease. The mechanisms behind this monocyte/macrophage activation are not known. Expression of the C5aR receptor on the surface of these populations, and preliminary findings of elevated C5a in these patients, suggest a potential role for this C5a-C5aR axis. Demonstration of the involvement of this pathway would open a path to therapeutic perspetives (C5aR inhibitors) for these patients, who frequently suffer from cortico-dependence and relapses. The aim of this research is to use healthcare technologies to identify cellular and molecular therapeutic targets in the context of the IgG4-associated disease

02

Conditions studied

  • Immunoglobulin G4-Related Disease
03

In context

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

This study's planned enrollment of 66 is above the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.

Browse Immunoglobulin G4-Related Disease studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for patients suffering from IG4-related disease and patients in remission :

  • age > 18
  • diagnosis of IgG4-associated disease according to ACR/EULAR 2019 classification criteria (4,5) with a score ≥20.
  • disease activity score (IgG4-RD Responder Index) ≥2 in at least one affected organ

Exclusion Criteria for patients suffering from IG4-related disease and patients in remission :

  • presence of a differential diagnosis ("IgG4-RD mimicker") or exclusion criterion according to ACR/EULAR 2019 classification criteria (4,5).
  • systemic treatment ≥5 mg/day ongoing or \< 1 month ; Study C5-MAG4_RCAPHM21_0433 Protocol Version 1.1 of 16/01/2024 Page 15 of 41
  • therapy ongoing or \< 3 months ;
  • current biotherapy treatment or \< 6 months;
  • absence of signed ;
  • absence of affiliation to a Social Security scheme.
  • patient participating in an ongoing therapeutic trial ;
  • any condition which, in the opinion of the investigator, could influence the results of the study.

Inclusion criteria

Inclusion criteria for healthy volunteers :

  • age > 18

Exclusion criteria

Exclusion criteria for healthy volunteers :

  • infectious episode (temperature >38°C, flu-like signs) in the 30 days prior to inclusion;
  • known inflammatory (including IG4-related disease) or pathology;
  • treatment with in progress or taken in the month prior to sampling, or in progress or taken in the 3 months prior to sampling, or biotherapy in the 6 months prior to sampling;
  • absence of signed ;
  • absence of affiliation to a Social Security scheme;
  • persons taking part in an ongoing therapeutic trial;
  • any condition which, in the opinion of the investigator, could influence the results of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    IgG4-RD patient

    Patients suffering from Immunoglobulin G4-related disease (IgG4-RD).

    Procedure: Blood sampling

  • Experimental
    patient in remission

    Patients suffering from Immunoglobulin G4-related disease (IgG4-RD) but in remission.

    Procedure: Blood sampling

  • Other
    healthy volunteers

    Procedure: Blood sampling

Interventions

  • ProcedureBlood sampling

    Blood sampling will be taken for further analysis

06

What researchers measure

Primary outcomes

  1. Serum C5a concentration

    The C5a concentration in the serum will be compared between of healthy volunteers and patients suffering from IG4-related disease

    Time frame: 24 months

Secondary outcomes

  1. frequency of C5aR1+ monocytes among total monocytes

    The frequency of C5aR1+ monocytes among total monocytes will be compared between : * patients suffering from IG4-related disease and healthy volunteers * patients suffering from IG4-related disease and patients in remission

    Time frame: 24 months

  2. frequency of Tumor Growth Factor B+ (TGF-B+) monocytes among total monocytes

    frequency of Tumor Growth Factor B+ (TGF-B+) monocytes among total monocytesill be compared between : * patients suffering from IG4-related disease and healthy volunteers * patients suffering from IG4-related disease and patients in remission

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Sep 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 21, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Sep 1, 2026
CompletionEst.
Apr 30, 2027
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06270524
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jun 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion